WO1998045464A1 - Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique - Google Patents

Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique Download PDF

Info

Publication number
WO1998045464A1
WO1998045464A1 PCT/SE1998/000626 SE9800626W WO9845464A1 WO 1998045464 A1 WO1998045464 A1 WO 1998045464A1 SE 9800626 W SE9800626 W SE 9800626W WO 9845464 A1 WO9845464 A1 WO 9845464A1
Authority
WO
WIPO (PCT)
Prior art keywords
animal
transgenic
factor
dna
anyone
Prior art date
Application number
PCT/SE1998/000626
Other languages
English (en)
Inventor
Marcela Pekna
Original Assignee
A+ Science Invest Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A+ Science Invest Ab filed Critical A+ Science Invest Ab
Priority to AU70902/98A priority Critical patent/AU7090298A/en
Publication of WO1998045464A1 publication Critical patent/WO1998045464A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Definitions

  • the present invention relates to a transgenic animal containing recombinant DNA having a modified nucleotide sequence from the complement factor B gene, and also to cells derived from said animal.
  • the transgenic animal and the cells thereof are useful for research and development in the fields of inflammatory reactions mediated by the complement system and for testing substances inhibiting the activation and/or the function of the complement sys- tern.
  • Complement or the complement system, is a system of more than 30 proteins found both in plasma and on cell membranes. Complement plays an essential role in the humoral immune response. Soluble complement components are present in the blood as inactive precursors and they need to be activated to fulfil their specific physiological roles. When activated, the system mediates the following functions: initiation of inflammation, neutralisation of pathogens, regulation of antibody responses, clearance of immune complexes and disruption of cell membranes. Under certain conditions complement can, however, act as a mediator of deleterious inflammatory reactions. The activation of the complement cascade occurs by three pathways, the classical pathway, the lectin pathway and the alternative pathway.
  • C3-convertase which is capable of activating the central molecule of the cascade, namely the third component (C3) .
  • the proteolytic activation of C3 generates the smaller C3a fragment with anaphylatoxic properties and the larger C3b fragment with the ability to bind to an activating surface and to trigger the terminal part of the cascade, at the end of which the terminal complement complex (TCC) is assembled on the target surface.
  • C3 is the central molecule of the complement cas- cade.
  • Factor B is an essential component of the alternative pathway C3 and C5 convertases which has the ability to proteolytically activate the components C3 and C5.
  • transgenic animal models are useful tools to study the functions and the physiological activities of proteins, and a variety of such animals have been produced for this purpose.
  • One particular technique for producing transgenic animals involves the process of homologous re- combination. In homologous recombination, all or part of a genomic sequence is replaced with another DNA containing homologous sequence.
  • a gene or part of a gene in the cells of an animal can be changed.
  • By changing the gene to encode a protein that no longer functions as the native protein one creates a null mutant or null allele (see, for example, U.S. Patent No. 5,557,032).
  • the present invention relates to a method for producing a transgenic, non-human animal containing modified factor B DNA, said method comprising the steps of: a) introducing a transgenic DNA into embryonic stem cells of the non-human animal, the transgenic DNA comprising a factor B DNA and having both a 5' region and 3' region of homology to the genomic factor B DNA of the em- bryonic stem cell; b) selecting an embryonic stem cell wherein the transgenic DNA has integrated into the genomic DNA; and c) introducing the selected cell from step b) into a blastocyst of a developing animal, and allowing the blas ⁇ tocyst to develop into a transgenic animal.
  • the 5' region of homology comprises exon 3 of the factor B gene and/or the 3' region of homology comprises exon 10 of the factor B gene.
  • tissue, cell cultures and cells from said animals are also referred to.
  • the transgenic non-human animal according to the invention is preferably a mammal, more preferably a rodent and most preferably a mouse.
  • the invention also relates to use of said animal, tissue, cell culture and/or cells for testing the involvement of the complement system in the pathogenesis of atherosclerosis; reactive gliosis and neurodegenerative diseases, such as Alzheimer's disease; decompression sickness, inflammatory bowel diseases, such as ulcerative colitis; rheumatoid and immune complex-mediated disease; bioincompatibility reactions; for screening a compound for treatment of complement deficiency; for testing the involvement of the complement system in mucosal immunity, per orally induced tolerance and vaccination; for screen- ing and testing a compound interfering with the activation of the complement system which regard to treatment and/or prevention of atherosclerosis; reactive gliosis and neurodegenerative diseases such as Alzheimer' s disease; decompression sickness, inflammatory bowel diseases such as ulcerative colitis; rheumatoid and immune complex-mediated disease; bioincompatibility reactions; for screening and testing a compound interfering with the ac- tivation of the complement system; and for
  • Fig. 1 shows a schematic representation of a strategy for producing a null mutation of the mouse factor B gene
  • Fig. 1A shows a restriction map of the factor B locus
  • Fig. IB shows a targeting DNA construct
  • Fig. 1C shows the location of the DNA probe and the Southern blotting screening strategy used to identify the wild-type and mutated factor B alleles
  • Fig. 2 shows a Southern blotting analysis of tail DNA from the F2 generation of wild-type (+/+) , het- erozygote (+/-) and homozygote knock out mice for the factor B locus (-/-)
  • Fig. 3 shows a schematic representation of the targeting construct building strategy: starting materials (constructs A-D) , intermediate steps (constructs E-F) , and final construct (construct G) .
  • Hogan (1994) A Laboratory Manual, edited by Hogan, B., et al., Cold Spring Harbor Laboratory Press, 1994, hereinafter referred to as "Hogan (1994)”. These documents are incorporated herein as reference. These documents may be relied on to enable a person skilled in the art to practice the invention.
  • biological material refers to any transgenic non-human animal according to the present invention, as well as to tissue, cell cultures and cells derived from said animal.
  • null allele refers to gene sequences encoding an altered protein as compared to the wild-type protein.
  • the "null mutant” is altered in a manner resulting in a protein substantially incapable of its primary function or in complete lack of a protein (i.e. no production).
  • a factor B null mutant is a DNA sequence encoding a very truncated protein with no functions known at present.
  • the "null mutant” can refer to the animal or cell bearing a gene sequence of an altered protein, as discussed above.
  • Transgenic DNA refers to DNA that is capable of being introduced into a cell so that the DNA is incorpo- rated into the genome of the cell.
  • the cell may be capable of giving rise to a transgenic animal, which contains the transgenic DNA.
  • the transgenic DNA is constructed as a vector, a transgenic vector, for administration into a particular cell.
  • a recombinant gene or sequence simply means the gene or sequence has been manipulated in any of a number of recombinant DNA techniques known in the art.
  • the process for generating transgenic animals is essentially the same regardless of the species involved. Briefly, transfected cells are injected into embryos at a stage at which they are capable of integrating the trans- fected cells, for example, at the blastocyst stage.
  • embryonic stem cells are available from a number of sources. These include mice, rats, cows, pigs, sheep, and other animals. For example, Joyner, A. L. de-scribes, in Gene Targeting, A practical approach, edited by Wood, R, and Hames, B. D., The Practical Approach Series, vol. 126, Oxford IRL Press, 1993 (specifically incorporated herein by reference) , methods for producing embryonic stem cells.
  • Hogan (1994) describes ma- nipulation of the mouse embryo.
  • Couly and Le Dourain, Development, 108:543-555, 1990 describe methods for isolating and manipulating chicken and quail embryos.
  • Kimmel and Warga describe in Nature, 327:234- 237, 1987 isolation and manipulation of zebrafish em- bryos. Ware et al . , Development of Embryonic Stem Cell
  • transgenic DNA can be microinjected into appropriate cells.
  • Viral vectors can be used to introduce the DNA into appropriate cells and the genome of those cells (see, for example, Tsukui et al., Nature Biotechnology, 14:982-985, 1996).
  • Cells can also be manipulated in vitro through transfection and electroporation methods (see Ausubel (1989) and Hogan (1994) .
  • transgenic DNA incorporates into a cell genome through either random integration or homologous recombination.
  • Persons skilled in the art are familiar with strategies for increasing the relative frequency of homologous recombination versus random integration, in embryonic stem cells and other cells, in order to iden- tify and isolate cells wherein homologous recombination has occurred (see e.g. Ausubel (1989), U.S. Patent No. 5,557,032., and Hogan (1994)).
  • the design of transgenic DNA vectors may involve incorporating some portion of the cellular sequence into the transgenic DNA, or a sequence homologous to the cellular sequence. That portion must be sufficiently homologous to the cellular sequence to allow the transgenic DNA and the cellular DNA to hybridise in vivo, for homologous recombination to occur.
  • the transgenic DNA to be inserted into an embryonic stem cell preferably comprises 5' and 3' regions of homology. These regions of homology function to allow the process of homologous recombination to occur in the embryonic stem cell.
  • homologous recombination does not occur for each cell where the transgenic DNA has been introduced.
  • some of the cells may incorporate the transgenic DNA at only one cellular sequence while other cells will incorporate the transgenic DNA into more than one cellular sequence, or even into every cellular sequence.
  • both homozygous and heterozygous animals may be produced from the embryonic stem cells subjected to homologous recombination with transgenic DNA.
  • a homozygous animal may be mated with wild-type animals to produce further transgenic animals heterozygotic for the transgenic DNA.
  • mice carrying mutated factor B alleles were generated.
  • One allele in the mice was functionally inactivated by the technique of homologous recombination in embryonic stem cells. Mice generated from these cells, thus, carried one mutant and one wild-type allele.
  • Fig. 1 composed of three subparts, 1A through 1C, is a schematic representation of the strategy followed in producing a null mutation of the mouse factor B gene.
  • the construct contains a 5' homologous fragment (BamHI/EcoRI, 5.0 kb) and a 3' homologous fragment (BamHI/BamHI, 1.3 kb) of the factor B gene, which flank the pPGK-neo- cassette (neo) .
  • Fig. 1C shows the location of the DNA probe used to identify wild-type and mutant alleles of factor B in Southern blot analysis.
  • Fig. 2 the migration of the wild-type and the recombinant Hindlll fragment after hybridisation with the DNA probe is shown.
  • Fig. 3 shows a schematic representation of the constructs A-G.
  • Example 1 Selection of factor B sequences useful as a transgene
  • the DNA used to generate a transgenic animal can contain a number of different DNA sequences. The selection of an appropriate sequence depends on the desired effect. For example, if an transgenic non-human animal possessing a null mutant of factor B is desired, the transgenic DNA contains sequences encoding a protein that is incapable of forming the C3 and C5 convertase of the alternative pathway of complement activation.
  • a portion of the mouse factor B gene was deleted.
  • the deleted portion contains the C- terminal part of the Ba domain and the first of the two serine protease domains as described by Bently, D. R. , Biochem. J. 239:339-345, 1986, and Ishikawa, N. et al., J. Biol. Chem. 265:19040-19046, 1990.
  • the three 5' exons encode the Ba fragment and the serine protease domain is encoded by 13 exons.
  • the gene for the mouse factor B was first cloned from a mouse ⁇ FIXII-library (Stratagene, La Jolla, CA) using pBmB2 (Sackstein, R. , et al., J. Biol. Chem. 258:14693-14697, 1983 as the probe.
  • a detailed restriction map of the genomic DNA was generated by digestion of the ⁇ DNA with different restriction enzymes followed by identification of the restriction fragments by Southern blotting.
  • the information obtained from the restriction map of the ⁇ DNA harbouring the factor B gene was used to select a DNA for transgenesis . From the restriction map shown in Fig. 1, one way of making a targeted, transgenic construct that would introduce a null mutation in the C3 gene is by deleting a restriction fragment. Replacement of the 1.8 kb EcoRI/BamHI fragment with PGK neo creates a null mutation.
  • Example 2 Production of transgenic vector with factor B deletion mutant
  • the C- terminal part of the Ba domain and the first of the two serine protease domains were removed. To do this, a 1.8 kb EcoRI/BamHI fragment was removed and replaced by pPGK neo.
  • the factor B protein generated from the targeted al- lele is non-functional as it lacks the C-terminal part of the Ba domain and the first of the two serine protease domains and the allele is thus a null allele.
  • the starting materials for the generation of a recombinant transgenic vector lacking the 1,8 kb EcoRI/BamHI fragment of factor B was a 5 kb BamHI/EcoRI fragment (used to generate the 5' region of the transgenic vector) from ⁇ -clone M, subcloned into plasmid pBluescriptTM (Stratagene) (construct A), a 3.0 kb Hindlll/Hindlll fragment from ⁇ -clone B, subcloned into plasmid pBluescriptTM (construct B) , a 1.7 kb pPGK neo cassette (Sibilia, M., Science 269:234-238, 1995) cloned into pBluescriptTM (construct C) and a 1.6 kb pPGK dTA cassette (see Yagi, T., et al., Analyt.
  • the pPGK neo was isolated by digesting construct C with Notl and EcoRI and blunting with Klenow fragment. The resulting 1.7 kb fragment was ligated into EcoRI di- gested and Klenow fragment blunted construct E, generating construct F.
  • the pPGK dTA was isolated by digesting construct D with Xhol.
  • the 1.6 kb fragment isolated on agarose gel was ligated into Sail digested construct F, generating construct G.
  • This vector containing 6.3 kb of DNA sequence homologous to the mouse factor B gene with the pPGK neo inserted in the backward direction, was chosen as the targeting vector for transgenesis .
  • the vector containing the mutant factor B (construct G) was transfected into E14.1 cells derived from the 129/Ola mouse (Kuhn, R. , et al., Science 254:707-710,
  • Neomycin resistant clones were isolated by standard procedures and characterised. "Hogan (1994)” describes procedures for isolating and manipulating embryonic stem cells. Genomic DNA from several hun- dred clones were isolated, Hindlll digested, and analysed by Southern blotting. Using these procedures, two positive clones denoted 10R and 19W were identified by detecting the 7.5 kb band and also the wild-type 2.8 kb band. This shows that one allele of the two factor B al- leles in the embryonic stem cells has been correctly targeted by the construct and that embryonic stem cells containing the null allele for factor were generated.
  • Example 4 Production of transgenic factor B animals
  • Cells from the cell line 10R were injected into mouse blastocysts using standard procedures. "Hogan (1994)” describes procedures for injecting cells into blastocysts. The blastocysts were implanted into pseudopregnant foster mothers. The resulting chimeric mice which were gener- ated, i.e. those possessing the transgenic DNA, were identified by the coat colour.
  • the embryonic stem cells were derived from the 129/OLA mouse with chinchilla (white- yellow) fur coat and carriers of the Agouti locus, whereas the host blastocysts were derived from the
  • the chimera will be a mixture of chinchilla (patches of skin to which only the host cells contributed) and brown or Agouti (patches of skin in which there was a mixture of 129/OLA and C57BL/6 cells) .
  • brown patches result from C57BL/6 hair follicle cells being stimulated by the Agouti protein, secreted from the 129/OLA cells, to proc- ess melatonin (black pigment) in such a way that the hair becomes brown.
  • mice Male chimeric mice were mated with wild-type C57BL/6 females. The presence of brown mice in the offspring from these females indicated germline transmission of the transgenic DNA.
  • DNA prepared from tails of these FI mice were analysed by Southern blotting as above. Generally, 0,5 cm of tail tissue was surgically removed and used to prepare DNA samples. The 7.5 kb Hindlll fragment was present in 50% of the brown (Agouti) mice indicating that there was no selection against the targeted null allele of factor B.
  • the Fl mice carrying the targeted factor B locus are heterozygous as they also carry a wild-type allele for factor B. The presence of normally developed Fl mice carrying one inactivated allele of factor B shows that gene dosage for factor B is not critical for survival.
  • Heterozyte Fl mice were crossed to generate mice homozygous for the inactivated factor B allele.
  • Example 5 Use of the transgenic non-human animal according to the invention as a model to study the involvement of the alternative pathway of complement activation in the pathogenesis of human disease
  • the transgenic non-human animal according to the invention can be used as a model to study the involvement of the alternative pathway of complement activation in the pathogenesis of human diseases, such as atherosclerosis; reactive gliosis and neurodegenerative diseases, such as Alzheimer's disease; decompression sickness, inflammatory bowel diseases, such as ulcerative colitis; rheumatoid and immune complex-mediated diseases; and bioincompatibility reactions.
  • human diseases such as atherosclerosis; reactive gliosis and neurodegenerative diseases, such as Alzheimer's disease; decompression sickness, inflammatory bowel diseases, such as ulcerative colitis; rheumatoid and immune complex-mediated diseases; and bioincompatibility reactions.
  • Atherosclerosis Recently, mice deficient for Apol- ipoprotein E (ApoE) were generated by gene targeting and were shown to develop lesions similar to those seen in human atherosclerosis (see Plump, A. S., et al., Cell 71:343-353, 1992, and Zhang, S. H. , et al., Science 258:468-471, 1992).
  • ApoE Apol- ipoprotein E
  • the factor B null allele can be crossed on the ApoE-/- background and the factor B-/-ApoE-/- mice can then serve as a test model to assess the effect of the factor B (and thus the alternative pathway of complement activation) deficiency on the time of onset and the progression of the atherosclerotic lesions as well as any potential treatment involving interference with the complement activation.
  • Reactive gliosis and Alzheimer's disease Recently, a mouse model for the Alzheimer' s diseases was developed by transgenic technology (see Games, D., et al., Nature, 373 (6514) :523-527, 1995).
  • the factor B deficient mice can be used to assess the contribution of the alternative pathway of complement activation to the inflammatory response and bioincompatibility reactions to various arti- ficial materials and to test the efficiency of any potential interference with the complement activation in this context .
  • Decompression sickness Recently it was demonstrated that mild changes occur in the complement system after decompression which was, however, insufficient to induce any signs of decompression sickness (see Pekna, M. , et al., Undersea Hyberbar. Med., 23:31-34, 1996).
  • mice can serve as a model to evaluate the role of the alternative pathway of complement activation in the pathogenesis of decompression sickness as well as to test any potential interference with the complement system as a treatment or prevention of this condition.
  • Ulcerative colitis It has been shown that G ⁇ i2 deficient mice generated by gene targeting develop inflam- matory bowel disease that is clinically and pathologically similar to ulcerative colitis in humans (see Rudolph, U. et al., Nature Genetics, 10:143-150, 1995). By breeding the factor B-/- allele on the G ⁇ i2-/- 129SV background, an animal model would be generated which would allow the testing of the role of the complement system in the development of ulcerative colitis as well as testing of any potential treatment of this condition by interference with the complement activation.
  • Rheumatoid and immune complex-mediated diseases The role of the early complement components in the pathogene- sis of rheumatoid arthritis can be tested by collagen type II immunisation of factor B-/- mice and evaluating the joint swelling and histology of the factor B-/- and control animals. For this purpose the factor B allele must first be bred on DBA/lLAcJ background. This model offers also the possibility to test the effects of a therapeutic interference with the activation of the complement cascade.
  • the factor B deficient mice can be monitored for the development of histological signs of glomerulonephritis which can ensue as a result of insufficient clearance of immune complexes from the circulation due to the inability to activate the complement cascade.
  • the factor B null allele can be bred on the New Zealand black (NZB) and New Zealand white (NZW) back- ground and factor B deficient NZB/NZW Fl females examined as to the course of the renal disease (histology, prote- inuria, survival) and compared with factor B+/- and factor B+/+ littermates. This model offers also the possibility to test the effects of a therapeutic interference with the activation of the complement cascade.
  • Example 6 Use of the transgenic non-human animal accordi:ng to the invention as a model to study the role of the alternative pathway of complement activation in mucosal immunity, per orally induced tolerance and per oral vaccination
  • the factor B deficient mice represent a model for the testing of the importance of the alternative pathway of complement activation for per orally induced tolerance and per oral vaccination and consequently the effects of the interference with the complement activation in this context .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à des animaux transgéniques, non humains, contenant de l'ADN de recombinaison possédant une séquence nucléotidique, modifiée, provenant du gène du facteur B, ainsi qu'à des cellules et à du tissu dérivés dudit animal. Elle se rapporte également à un procédé de production dudit animal, ainsi qu'à l'utilisation dudit animal, des cellules et du tissu dérivés pour analyser l'implication du complément dans diverses maladies et pour sélectionner des composés interférant avec l'activation du complément.
PCT/SE1998/000626 1997-04-09 1998-04-06 Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique WO1998045464A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU70902/98A AU7090298A (en) 1997-04-09 1998-04-06 Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method of producing said transgenic animal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9701345A SE9701345D0 (sv) 1997-04-09 1997-04-09 Transgenic, non-human animal with protein deficiency, cells derived therefrom, use of said animal and cells, and method ofpr oducing said transgenic animal
SE9701345-2 1997-04-09

Publications (1)

Publication Number Publication Date
WO1998045464A1 true WO1998045464A1 (fr) 1998-10-15

Family

ID=20406532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1998/000626 WO1998045464A1 (fr) 1997-04-09 1998-04-06 Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique

Country Status (3)

Country Link
AU (1) AU7090298A (fr)
SE (1) SE9701345D0 (fr)
WO (1) WO1998045464A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021559A2 (fr) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Facteur de blocage b destine a traiter une maladie d'origine immunitaire induite par complement

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF CLINICAL IMMUNOLOGY, Volume 15, No. 6, November 1995, MICHAEL M. FRANK, "Animal Models for Complement Deficiencies", page 113. *
MOLECULAR CELL BIOLOGY, 3 Ed., 1995, by SCIENTIFIC AMERICAN BOOKS, INC., JAMES DARNELL, pages 293-294. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021559A2 (fr) * 1998-10-09 2000-04-20 Musc Foundation For Research Development Facteur de blocage b destine a traiter une maladie d'origine immunitaire induite par complement
WO2000021559A3 (fr) * 1998-10-09 2000-09-28 Musc Found For Res Dev Facteur de blocage b destine a traiter une maladie d'origine immunitaire induite par complement

Also Published As

Publication number Publication date
SE9701345D0 (sv) 1997-04-09
AU7090298A (en) 1998-10-30

Similar Documents

Publication Publication Date Title
US20200359610A1 (en) Humanized transgenic animal
JP3258024B2 (ja) Ｉｉ型真性糖尿病のトランスジェニック動物モデル
JP2010516258A (ja) Ｃ反応性タンパク質（ｃｒｐ）ノックアウトマウス
US6262337B1 (en) Transgenic animal with recombinant vascular endothelial growth factor B (VEGF-B DNA) and uses thereof
Nakayama et al. A gene‐targeting approach for functional characterization of KIAA genes encoding extremely large proteins
WO2001056375A1 (fr) Mammifere non humain mort a gene tob defectueux
WO1994009621A1 (fr) Souris deficiente en fonction genique d'endotheline 1
WO1997035967A2 (fr) Organismes transgeniques presentant une alteration de l'activite de la telomerase
US6077990A (en) PAR2 modified transgenic mice
WO1998045464A1 (fr) Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique
WO1998045465A1 (fr) Animal transgenique, non humain, a carence proteique, cellules derives de cet animal, utilisation dudit animal et desdites cellules, et procede de production dudit animal transgenique
US6194633B1 (en) Non-human animal having a functionally disrupted SLP-76 gene
EP1208200B1 (fr) Modele d'animal transgenique destine a des maladies neurogeneratives
Prosser et al. Targeted replacement of rodent CCR2 with the human orthologue CCR2B: A mouse model for in vivo analysis of human target‐selective small molecule MCP‐1 receptor antagonists
US20070061898A1 (en) Transgenic mouse expressing a polynucleotide encoding human tissue factor
JPH10509586A (ja) 機能的に破壊されたインターロイキン−１β変換酵素遺伝子を有するトランスジェニック非ヒト動物
JP2004267002A (ja) セネッセンスマーカープロテイン３０欠損動物、抗体およびその作製方法
WO2006085673A1 (fr) Animal transgenique sans poils
CA3155265A1 (fr) Modele de rongeur a densite minerale osseuse accrue
US20090007283A1 (en) Transgenic Rodents Selectively Expressing Human B1 Bradykinin Receptor Protein
JP2001299141A (ja) ノックイン非ヒト哺乳動物
JP4303907B2 (ja) ラディキシンノックアウト動物
JPH1033087A (ja) グルタミン酸トランスポーター遺伝子機能欠損非ヒト動物
JP2003319735A (ja) Ｐｓ−ｐｌａ１遺伝子機能欠損動物及びその用途
JPH10295216A (ja) ボンベシン様ペプチド受容体遺伝子機能欠損非ヒト動物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998542690

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA